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In this thesis, we aim to (1) uncover novel (epi)genetic regulatory mechanisms 
that affect endothelial plasticity as an underlying cause of organ fibrosis, and (2) 
to therapeutically target (epi)genetic regulatory mechanisms to combat organ 
fibrosis. We identified relevant epigenetic changes during endothelial-to-
mesenchymal transition (EndMT), a specific form of endothelial plasticity, in 
different disease contexts and investigated the impact of different EndMT triggers 
(such as hypoxia and high glucose) and unraveled the epigenetic changes they 
induce. Moreover, we have investigated their relevance to the induction and 
progression of EndMT. Also, we performed stage-specific mapping of EndMT to 
identify genetic regulatory mechanisms that drive the active stage of transition. 
For the second aim, we demonstrate that Serelaxin, a recombinant form of the 
human Relaxin-2 hormone, alleviates cardiac fibrosis in part through the 
inhibition of EndMT. We also discussed the mechanisms involved in the reciprocal 
relationship between chronic kidney disease and cardiac fibrosis and identified 
microRNAs as potential profibrotic kidney-heart messengers. Moreover, we 
identified relevant possibilities and in vivo applications of CRISPR/Cas derivatives. 
This gene modulating tool is applied to target epigenetic modifications which 
alleviate both renal and cardiac fibrosis. In conclusion, in this thesis we have 
shown that in fibroproliferative diseases, endothelial plasticity is highly regulated 
by epigenetic modifications (part I). These epigenetic modifications may offer new 
therapeutic approaches. Indeed, we demonstrate that epigenetic modifications 
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1 INTRODUCTION AND AIMS  
 
Organ fibrosis is characterized by the progressive deposition of extracellular 
matrix which replaces functional tissue and results in structural alterations and 
eventually loss of function, contributing to organ dysfunction (e.g. heart failure). 
The excessive extracellular matrix is produced by different cell types, such as 
activated fibroblasts, so-called myofibroblasts, and myofibroblast-like cells 
derived from endothelial cells via a process called endothelial-to-mesenchymal 
transition (EndMT) [1-4]. As of yet, no specific anti-fibrotic therapy is available. 
Endothelial cells line the inner side of blood (or lymphatic) vessels and are in 
direct contact with the blood. Endothelial cells form the barrier between the 
blood and the surrounding tissue, and have several important functions such as 
regulating vascular permeability and the trafficking of leukocytes to the 
surrounding tissue [5,6]. The dynamic environment (including both biochemical 
stimuli and mechanical forces) requires endothelial cells to be highly adaptive [7]. 
This endothelial plasticity can be advantageous, but adverse plasticity can also 
contribute to disease. 
EndMT is a specific form of endothelial plasticity, and was originally 
discovered during cardiac valve development, but is now increasingly recognized 
for its contribution to pathologies such as cardiovascular disease [8-10], organ 
fibrosis [3,4,11] and cancer [12,13]. EndMT is characterized by the loss of 
endothelial markers and the upregulation of EndMT transcription factors as well 
as mesenchymal markers. EndMT-derived mesenchymal cells acquire a highly 
migratory and invasive phenotype which is accompanied by morphological 
changes from a cobble-stone endothelial morphology into a spindle-shaped 
myofibroblast-like morphology. EndMT is triggered by a variety of external stimuli 
such as the lack of oxygen (hypoxia), high glucose concentrations or pro-
inflammatory cytokines [14-16]. These environmental factors trigger the 
activation of signaling pathways which induce EndMT such as the canonical 
Transforming Growth Factor Beta (TGF-β) pathway or the non-canonical 
pathways such as Notch [17]. However, the underlying molecular mechanisms 
that drive EndMT remain largely unknown. 
Epigenetics is a way of regulating gene expression independent of changes in 
the nucleotide sequence, and has been increasingly linked to EndMT [18,19]. 
Epigenetic regulation includes DNA promoter methylation, histone modifications 
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and non-coding RNAs, which each individually or in concert influence gene 
transcription. Epigenetic regulation was originally identified as a determinant for 
cellular differentiation during development but is increasingly recognized for its 
association with cardiovascular disease, organ fibrosis and cancer [20-25]. 
Because EndMT (1) is originally a developmental process, (2) is a form of cellular 
plasticity by which extensive gene expression changes are necessary, and (3) 
contributes to diseases which are associated with epigenetic regulation, 
epigenetics is considered as a strong candidate regulator of EndMT [18]. 
The aims of this thesis are to (1) uncover novel (epi)genetic regulatory 
mechanisms that affect EndMT and (2) to therapeutically target (epi)genetic 
regulatory mechanisms to combat organ fibrosis.  
 
 
OUTLINE OF THE THESIS  
 
The first part of the thesis focuses on the epigenetic regulation of EndMT in 
the context of cardiovascular disease. Chapter 2 starts with an overview of the 
signaling pathways and modulators of EndMT including profibrotic cytokines (e.g. 
TGF-β), hypoxia (the lack of oxygen) and high glucose. The focus of Chapter 2 
includes a summary of the epigenetic mechanisms (i.e. histone modifications, 
DNA methylation and non-coding RNAs) which influence EndMT in the context of 
chronic heart disease. Having identified the relevant epigenetic changes (Chapter 
2), in the next two chapters we investigated the impact of different EndMT 
triggers (i.e. hypoxia and high glucose) and unraveled the epigenetic changes they 
induce. In Chapter 3 we examine the possible involvement of DNA promoter 
methylation of the anti-fibrotic gene RASAL1 in hypoxia-induced EndMT. In 
Chapter 4 we investigate the contribution of the non-coding RNA miR-132-3p and 
the transcription factor KLF7 in glucose-induced EndMT and the related aortic 
stiffening in diabetes. Besides cardiovascular disease, EndMT contributes to other 
pathologies including chronic kidney disease. Chapter 5 describes the 
mechanisms by which non-coding RNAs facilitate or inhibit EndMT during 
development and diseases. In the last chapter of part I, Chapter 6, we performed 
stage-specific mapping of EndMT to identify regulatory mechanisms that drive 
the active stage of transition.  
546222-L-bw-Hulshoff
Processed on: 27-10-2020 PDF page: 13
   ABSTRACT, INTRODUCTION AND AIMS   
13 
 
1 The second part of the thesis focuses on the therapeutic targeting of 
epigenetic mechanisms to combat organ fibrosis. We explore in Chapter 7 the 
anti-fibrotic effect of Serelaxin, a recombinant form of the human Relaxin-2 
hormone, in the heart. Serelaxin exerts vasodilating, anti-inflammatory and anti-
fibrotic effects and might therefore be of interest to target chronic heart failure.  
Chapter 8 describes the mechanisms by which chronic kidney disease may cause 
cardiac fibrosis. Several (potential) modulators are discussed including non-
coding RNAs.  Chapter 9 describes different genome editing tools, the variety of 
Cas proteins and most importantly the possibilities and in vivo applications of 
CRISPR/Cas derivatives to perform gene modulation. The CRISPR/Cas sytem was 
originally discovered in bacteria and is now used to cleave mammalian DNA or 
RNA. Deactivation of the cleavage capacity of the CRISPR/Cas system enables to 
fuse Cas to other effector domains thereby enabling distinct possibilities to use 
the CRISPR/Cas system. In Chapter 10 we use the deactivated CRISPR/Cas system 
to perform gene-specific reactivation of the anti-fibrotic genes (including RASAL1) 
which results in the amelioration of kidney fibrosis. After the successful 
establishment of this system to prevent experimental kidney fibrosis, we transfer 
this system to the heart to treat experimental cardiac fibrosis (Chapter 11).  
The final part of the thesis includes a Research Summary and an Epilogue 
including discussion and future perspectives.  
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